Inside the Closed-Loop Revolution: Saluda's Bid to Redefine Chronic Pain Treatment

In this episode of Vantage Point, we’re joined by Saluda Medical CEO Barry Regan for an insightful discussion around one of the ASX’s most compelling medtech growth stories. Drawing on more than three decades across medtech, biotech and pharma, Barry reflects on the experiences that shaped his career and what drew him to Saluda. We explore how the company’s Evoke® system is transforming the spinal cord stimulation market through its innovative and differentiated closed-loop technology, delivering a personalised, responsive and clinically superior approach to pain management. The discussion also covers the scale of the US$23B chronic pain market, limitations of incumbent therapies, the burden of opioids, and how Saluda is delivering a true step-change in the standard of care. Barry also elaborates on the strategy behind scaling its US commercial footprint and execution currently underway.